AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? AbbVie is raising its outlook with Skyrizi and Rinvoq offsetting Humira losses. Pfizer is rebuilding its pipeline around obesity drugs and key readouts expected over the next year.
Forget Treasury Bonds: This 6%-Yielding Pharma Stock Pays You to Wait for Its Pipeline A reliable payout, a growing cancer treatment lineup, and improving guidance make this drugmaker worth a second look right now.
Branded Pharmaceuticals Stocks Q2 In Review: Zoetis (NYSE:ZTS) Vs Peers As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking a...
Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? Johnson & Johnson trades at a higher valuation with growing sales, while Pfizer's dividend yield is near 6% as patents expire from 2026 through 2030.
Better Invesco Healthcare ETF: PJP Targeting Pharmaceuticals vs. RSPH's Broader Sector Lens PJP's one-year return beats RSPH's, but RSPH offers broader diversification across 61 healthcare holdings at a lower expense ratio.
How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends? You'll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and Bristol Myers Squibb.
Better Pharma ETF: iShares IHE vs. State Street XPH IHE concentrates 23.6% in Eli Lilly and delivers 1.4% yield, while XPH spreads risk across 62 holdings with a lower 0.35% expense ratio.
Alnylam vs. Ionis: Here's the Better Bad-News Buy The sell-offs for both of these beaten-down biotech stocks appear to be overdone.
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? Both face patent cliffs and regulatory headwinds, but their balance sheets and cash generation tell starkly different stories.
2 Growth Stocks to Buy in October Grail and Veeva Systems could be well insulated from near-term headwinds.
Pfizer Stock: Buy, Sell, or Hold? The company is entering what could be a particularly challenging period.
D-Wave Quantum vs. Rigetti Computing: Which Cutting Edge Quantum Stock Is a Better Buy in 2026? D-Wave is growing revenue at nearly 180% while Rigetti trades at a lower valuation, but both burn cash heavily and face unproven commercial roadmaps.
1 Healthcare Stock with Competitive Advantages and 2 We Find Risky Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva...
3 of the Best Dividend Stocks to Buy in October 2026 A couple of the stocks on this list pay more than 6% in dividends.
2 Unpopular Stocks That Should Get More Attention and 1 Facing Challenges Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...
Eli Lilly Has Been a Growth Beast, but This Is the Riskiest Part About Its Stock The healthcare stock's elevated valuation bakes in high expectations, leaving little room for error.
Why Pfizer Might Be the Most Underrated Dividend Stock to Buy Right Now Many dividend investors may be overlooking Pfizer's stock, and that could be a costly mistake.
Eli Lilly vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? Eli Lilly is dominating the GLP-1 market with nearly 50% revenue growth and a newly approved oral obesity pill. Pfizer is rebuilding its pipeline with obesity drug ambitions and a committed dividend through its transformation.
Vaxcyte Catapults After Going Toe-To-Toe With Pfizer, Merck In Vaccine Study Vaxcyte stock catapulted Monday after its pneumococcal vaccine proved it's not inferior to shots from Pfizer and Merck.
Better High-Yield Dividend Stock: Pfizer or Novo Nordisk? Novo Nordisk covers its dividend, and Pfizer doesn't, but investors appear increasingly worried about Novo's future.
